Nanobiotix Reports 41.7% Response Rate in Phase 1 Melanoma Trial
Nanobiotix reported a 41.7% response rate in a Phase 1 trial of its NBTXR3 combination for resistant melanoma.
Nanobiotix reported a 41.7% response rate in a Phase 1 trial of its NBTXR3 combination for resistant melanoma.